Table 1.

Therapy-related side-effects of T cells gene-engineered with TCR and iIL-12 and/or iIL-18.

Treatment	Maximum weight lossa	Edemab	Therapy-related deathc	Overall survivald
mock	57%	0%	0%	0%
TCR only	11%	0%	0%	29%
TCR+iIL-12	78%	29%	43%	14%
TCR+iIL-18	0%	0%	0%	57%
TCR+iIL-12+iIL-18	56%	29%	29%	43%

^apercentage of mice showing a loss of weight exceeding 10% of starting weight (day -15).

^bpercentage of mice developing edema; mice were scored positive for edema according to both, visual evaluation by a pathologist and increase in body weight of >3.0% per day over a period of 7 or more days.

^cpercentage of mice dying within the first 10 days after T cell administration while no tumor growth was detected.

^dpercentage of mice alive at day 45.